Highest-materiality recent filing
QuidelOrtho Q1 net loss $92M; revenue $620M; cuts full-year guidance
GAAP net loss $92M ($1.35 diluted loss per share); adjusted diluted EPS loss $0.04; revenue $620M.
QuidelOrtho prelim Q1 rev $615-620M; weaker respiratory season, China headwinds
Prelim Q1 2026 revenue of $615-$620M; U.S. flu-like illness visits down ~30% YoY.
QuidelOrtho appoints Nate Sisitsky as Chief Legal Officer; Michelle Hodges retires
Michelle Hodges retires as Chief Legal Officer and Corporate Secretary effective March 23, 2026; will serve as special advisor for up to 24 months.
CFO Joseph M. Busky to retire effective June 30, 2026
Joseph M. Busky notified QuidelOrtho of his retirement on February 9, 2026.
QuidelOrtho reports FY25 revenue $2.73B, adjusted EBITDA $597M; guides FY26 revenue $2.7-2.9B
FY25 total revenue $2.73B in line with guidance; Labs revenue +6% as reported, non-respiratory +5% ex Donor Screening.
Director Matthew W. Strobeck to not stand for re-election; Board will reduce to 10
Matthew W. Strobeck notified Board on Jan 30, 2026 of decision not to stand for re-election at 2026 annual meeting.
QuidelOrtho Q3: revenue $700M, adj. EBITDA margin 25%, core growth 5% YoY
Total revenue $700M; core revenue (ex-COVID/Donor Screening) grew 5% as reported.
QuidelOrtho Q3 revenue $700M (-4% YoY); GAAP loss $10.78/sh on $701M impairment; Adj EPS $0.80
Total revenue $700M, down 4% YoY; non-respiratory revenue up 5% as reported, 6% constant currency ex-Donor Screening.
QuidelOrtho refinances with $1.15B Term Loan A, $1.45B Term Loan B, $700M revolver
New credit facility includes $1.15B 5-yr Term Loan A, $1.45B 7-yr Term Loan B, $700M revolver, and $100M delayed draw Term Loan A (undrawn).
QuidelOrtho reports Q2 2025 adjusted EPS of $0.12 vs loss of ($0.07); reaffirms FY guidance
Q2 revenue $614M (-3.6% YoY); Labs revenue +4% as reported, but respiratory revenue fell 20% to $47M on lower COVID-19 sales.
QuidelOrtho stockholders approve 6.2M share increase for equity plan, reelect 11 directors
Stockholders approved Second A&R 2018 Equity Incentive Plan, increasing authorized shares by 6.2M and extending term to May 20, 2035.
QuidelOrtho Q1 revenue $693M, +5% ex-COVID/Donor; adjusted EPS $0.74 vs $0.44 YoY
Total revenue $693M, -3% reported due to lower COVID/Donor; ex-COVID/Donor +5% as reported and +6% constant currency.
QuidelOrtho appoints KPMG as auditor, dismisses EY; material weaknesses disclosed
Audit Committee selected KPMG as independent auditor for FY 2025, dismissing EY effective Feb 28, 2025, after competitive process.
Q4 GAAP diluted loss per share $2.28 vs EPS $0.10 prior year; adjusted EPS $0.63 vs $1.17.
QuidelOrtho expects Q4 2024 revenue of $702-707M, above guidance midpoint
Preliminary total revenue $702-707M, in line with prior guidance; non-respiratory $561-563M, respiratory $141-143M.
QuidelOrtho appoints John Chiminski and Scott Huennekens as independent directors
Appointments effective December 6, 2024; both qualify as independent under Nasdaq rules.
Carlyle sells 8.26M QuidelOrtho shares at $35.31; two Carlyle directors resign
Carlyle Partners VI sells 8,260,183 QDEL shares at $35.31/share; company receives no proceeds.
QuidelOrtho appoints Philip McLellan as COO, approves salary increase to $515K
Philip McLellan appointed Chief Operations Officer effective November 15, 2024.
QuidelOrtho expands CFO Busky's role to include IT oversight; salary raised to $680,000
CFO Joseph Busky assumes additional oversight of Information Technology function effective Nov 18, 2024.
QuidelOrtho terminates EVP CCO and EVP COO; appoints Philip McLellan as COO
Terminated Michael S. Iskra (EVP & CCO) and Robert J. Bujarski (EVP & COO), effective Nov 15, 2024.
QuidelOrtho Q3 GAAP net loss $20M ($0.30 EPS); revenue $727M; reinstates 2024 guidance
Revenue $727M vs $744M YoY; Labs revenue grew 4% as reported (5% constant currency).
QuidelOrtho Q2 2024: revenue $637M, GAAP diluted loss ($2.20)/share
Total revenue $637M, down 4% YoY; lower COVID-19 revenue was primary driver.
QuidelOrtho stockholders elect all 10 director nominees, approve say-on-pay, ratify EY as auditor
Ten directors elected with 97.5% to 90.9% of votes cast; highest support for Evelyn Dilsaver (95.6%), lowest for Kenneth Widder (90.9%).
QuidelOrtho Q1 revenue $711M, GAAP loss $25.50/share; suspends 2024 guidance after new CEO
Total revenue $711M, down 16% YoY; ex-COVID revenue grew 5% as reported (6% constant currency).
QuidelOrtho appoints Brian J. Blaser as CEO effective May 6, 2024
Blaser, ex-Abbott EVP Diagnostic Products, replaces interim CEO Michael Iskra and interim President Robert Bujarski.
QuidelOrtho amends credit agreement; leverage ratio covenant adjusted through 2025
Amendment temporarily raises max leverage to 4.25x for Q3/Q4 2024, then to 4.00x, stepping to 3.75x after June 2025.
the Company appointed Philip McLellan to serve as the Company’s Chief Operations Officer (“COO”), effective November 15, 2024.
Joseph M. Busky, the Company’s Chief Financial Officer, assuming additional responsibilities, including oversight of the Company’s Information Technology function, on November 18, 2024
In addition, the Company appointed Philip McLellan to serve as the Company’s Chief Operations Officer, effective as of the Effective Date.
The Company determined to terminate the employment of Michael S. Iskra, the Company’s Executive Vice President (“EVP”) and Chief Commercial Officer, and Robert J. Bujarski, the Company’s EVP and Chief Operating Officer, each effective November 15, 2024 (the “Effective Date”).
The Company determined to terminate the employment of Michael S. Iskra, the Company’s Executive Vice President (“EVP”) and Chief Commercial Officer, and Robert J. Bujarski, the Company’s EVP and Chief Operating Officer, each effective November 15, 2024 (the “Effective Date”).
The Board of Directors (the “Board”) of QuidelOrtho Corporation (the “Company”) has appointed Brian J. Blaser to serve as the Company’s President and Chief Executive Officer, effective as of May 6, 2024 (the “Effective Date”).
each of Michael S. Iskra, who served as the Company’s Interim Chief Executive Officer, and Robert J. Bujarski, who served as the Company’s Interim President, stepped down from these interim positions.
In addition, effective as of May 15, 2024, the Board expanded its size from ten to eleven directors and appointed Mr. Blaser to serve as a director until the Company’s 2025 Annual Meeting of Stockholders.
each of Michael S. Iskra, who served as the Company’s Interim Chief Executive Officer, and Robert J. Bujarski, who served as the Company’s Interim President, stepped down from these interim positions.
Max materiality 0.85 · Median 0.65 · Most common event earnings